Pulmonary Nodule Smart Manager · Follow-up & Surgical Decision — free guideline decision tool

This tool turns nodule type, size, scenario, risk, and dynamics into classification, malignancy stratification, follow-up, diagnostic approach, surgical window, and procedure recommendation in one pass.

Screening → Lung-RADS category by type/size/solid component. Incidental → Fleischner by type and size.

Use to classify by Lung-RADS (screening) or Fleischner (incidental), refine follow-up with the Chinese 2024 consensus, and gauge the surgical window and procedure.

(original synthesis · not guideline verbatim) Pure GGN is prone to PET false-negatives and a long doubling time does not exclude indolent adenocarcinoma. Solid-component size and growth are the core invasiveness markers driving escalation. China reference line: the China National Lung Cancer Screening Guideline with LDCT (2025 Version), read side by side with Lung-RADS. This tool's screening categories follow Lung-RADS v2022. This tool does not calculate by those criteria. Quality control (Oncology Society of Chinese Medical Association, 2026): target mean effective dose for LDCT < 1 mSv; use iterative or deep-learning reconstruction where available; AI reads must be reviewed by a radiologist (false negatives occur in central and mediastinal lesions). Two site rules (not guideline text): low-dose CT from a health-check centre is treated as screening (Lung-RADS), while standard-dose health-check chest CT is treated as incidental (Fleischner)

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.

Inputs: Detection scenario Checkup/incidental (Fleischner), Nodule type Part-solid, Mean diameter = (long axis + short axis) / 2 9 mm, Solid-component diameter (required for part-solid) 5 mm, Lung-cancer risk Low risk, Compared with prior CT Stable on follow-up, Number Single, Location (affects procedure) Peripheral (outer 1/3) → Result: Conclusion [Pending update] Some thresholds, grades and management recommendations on this page that conflict with current guidelines or are unverified are temporarily hidden pending verification against the guideline text. · follow-up primary（Classification: [Pending update] Some thresholds, grades and management recommendations on this page that conflict with current guidelines or are unverified are temporarily hidden pending verification against the guideline text. (malignancy probability low-intermediate), (1) Follow-up strategy: CT at 3–6 months to confirm persistence; → annual CT for 5 years., (2) Diagnostic approach: Serial thin-section CT follow-up primary; upgrade if enlarging or a solid component appears. Markers (CEA/Cyfra21-1/SCC/ProGRP) may be tracked but not as a sole basis.） Inputs: Detection scenario Checkup/incidental (Fleischner), Nodule type Solid, Mean diameter = (long axis + short axis) / 2 9 mm, Solid-component diameter (required for part-solid) 5 mm, Lung-cancer risk Low risk, Compared with prior CT Baseline/first detection, Number Single, Location (affects procedure) Peripheral (outer 1/3) → Result: Conclusion [Pending update] Some thresholds, grades and management recommendations on this page that conflict with current guidelines or are unverified are temporarily hidden pending verification against the guideline text. · surgical-assessment window（Classification: [Pending update] Some thresholds, grades and management recommendations on this page that conflict with current guidelines or are unverified are temporarily hidden pending verification against the guideline text. (malignancy probability ~3%+, assess by probability), (1) Follow-up strategy: Enter active assessment: choose one of CT at 3 months / PET-CT / tissue sampling., (2) Diagnostic approach: non-surgical biopsy — peripheral nodules CT-guided transthoracic needle biopsy (TTNB), central/needing mediastinal staging use bronchoscopy + EBUS-TBNA; indeterminate nodules (highly suspected early cancer but biopsy inconclusive) → MDT + shared decision-making.）